Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top Correlated Resources
AYTU
Top 10 Correlated ETFs
AYTU
Top 10 Correlated Stocks
AYTU
In the News
Aytu BioPharma, Inc. (AYTU) CEO Josh Disbrow on Q4 2022 Results - Earnings Call Transcript
Start Time: 16:30 January 1, 0000 5:12 PM ET Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q4 2022 Earnings Conference Call September 27, 2022, 16:30 PM ET Company Participants Josh Disbrow - Chairman and CEO Mark Oki - CFO Robert Blum - Lytham Partners Conference Call Participants Vernon Bernardino - H.C. Wainwright Sumant Kulkarni - Canaccord Operator Good afternoon everyone and welcome to Aytu BioPharma's Fourth Quarter and Fiscal Year 2022 Financial Results Conference Call.
Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022
ENGLEWOOD, CO / ACCESSWIRE / September 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, will report financial results for its fourth quarter and fiscal year ended June 30, 2022, after the market close on Tuesday, September 27, 2022. The Company has scheduled a conference call that same day, Tuesday, September 27, 2022, at 4:30 pm ET, to review the results.
Aytu BioPharma to Participate in September 2022 Investor Conferences
ENGLEWOOD, CO / ACCESSWIRE / August 24, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, today announced that Aytu's management team will virtually present at, and participate in, the upcoming H.C. Wainwright 24th Annual Global Investment Conference and Lytham Partners Fall 2022 Investor Conference.
Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320%
Here's what you need to know about trading penny stocks on April 19th The post Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year?
Here is how Aytu BioPharma Inc. (AYTU) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Aytu BioPharma's (AYTU) AR101 Gets FDA's Orphan Drug Status
The FDA bestows an Orphan Drug designation to Aytu BioPharma's (AYTU) AR101 for the treatment of vascular Ehlers-Danlos Syndrome.
Aytu Biopharma, Inc. (AYTU) CEO Josh Disbrow on Q1 2022 Results - Earnings Call Transcript
Aytu Biopharma, Inc. (AYTU) CEO Josh Disbrow on Q1 2022 Results - Earnings Call Transcript
Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021
ENGLEWOOD, CO / ACCESSWIRE / November 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on November 15, 2021, at 4:30 p.m. ET. The Company will review accomplishments from the first quarter fiscal 2022 and provide an overview of its business and growth strategy.
Aytu BioPharma Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Aytu BioPharma Inc. (AYTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALERT: Rowley Law PLLC is Investigating Potential Breaches of Fiduciary Duty by the Aytu BioPharma, Inc. Board of Directors
NEW YORK, Oct. 4, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating a potential breach of fiduciary duty claim involving the board of directors of Aytu BioPharma, Inc. (NASDAQ: AYTU). If you are a stockholder of Aytu BioPharma, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/aytu /.
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-06-30
| Metric | History | 2017-06-30 | 2018-06-30 | 2019-06-30 | 2020-06-30 | 2021-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.38K | 54.99 | 9.39 | 6.11 | 3.92 | |
| Net income per share | -9.66K | -153.06 | -34.81 | -3.01 | -3.48 | |
| Operating cash flow per share | -5.94K | -239.49 | -17.75 | -6.28 | -1.55 | |
| Free cash flow per share | -5.98K | -240.61 | -17.82 | -6.28 | -1.55 | |
| Cash per share | 344.35 | 105.36 | 14.17 | 10.64 | 2.96 | |
| Book value per share | 1.72K | 201.69 | 9.09 | 21.02 | 8.21 | |
| Tangible book value per share | -3.14K | 30.93 | -15.39 | 4 | -0.82 | |
| Share holders equity per share | 1.72K | 201.69 | 9.09 | 21.02 | 8.21 | |
| Interest debt per share | 1.09K | 11.26 | 0 | 0.56 | 1.69 | |
| Market cap | 5.5M | 3.73M | 12.47M | 61.91M | 66.48M | |
| Enterprise value | 4.7M | -3.29M | 1.43M | 16.35M | 45.18M | |
| P/E ratio | -0.24 | -0.37 | -0.46 | -4.55 | -1.14 | |
| Price to sales ratio | 1.71 | 1.02 | 1.7 | 2.24 | 1.01 | |
| POCF ratio | -0.4 | -0.23 | -0.9 | -2.18 | -2.56 | |
| PFCF ratio | -0.39 | -0.23 | -0.9 | -2.18 | -2.56 | |
| P/B Ratio | 1.37 | 0.28 | 1.76 | 0.65 | 0.48 | |
| PTB ratio | 1.37 | 0.28 | 1.76 | 0.65 | 0.48 | |
| EV to sales | 1.46 | -0.9 | 0.19 | 0.59 | 0.69 | |
| Enterprise value over EBITDA | -0.3 | 0.48 | -0.06 | -2.22 | -0.93 | |
| EV to operating cash flow | -0.34 | 0.21 | -0.1 | -0.58 | -1.74 | |
| EV to free cash flow | -0.34 | 0.21 | -0.1 | -0.58 | -1.74 | |
| Earnings yield | -4.09 | -2.73 | -2.18 | -0.22 | -0.88 | |
| Free cash flow yield | -2.54 | -4.3 | -1.11 | -0.46 | -0.39 | |
| Debt to equity | 0 | 0 | 0 | 0.01 | 0.02 | |
| Debt to assets | 0.73 | 0.36 | 0.8 | 0.38 | 0.48 | |
| Net debt to EBITDA | 0.05 | 1.02 | 0.45 | 6.18 | 0.44 | |
| Current ratio | 0.84 | 2.79 | 2.87 | 2.65 | 0.96 | |
| Interest coverage | -7.94 | -26.29 | 0 | 0 | 0 | |
| Income quality | 0.61 | 1.56 | 0.51 | 2.08 | 0.45 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 5.46 | 4.84 | 2.63 | 0 | 0.39 | |
| Research and developement to revenue | 0.42 | 0.05 | 0.08 | 0.06 | 0.09 | |
| Intangibles to total assets | 0.75 | 0.54 | 0.55 | 0.5 | 0.57 | |
| Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.03 | -0.02 | -0.01 | 0 | 0 | |
| Capex to depreciation | -0.03 | -0.03 | -0.02 | 0 | 0 | |
| Stock based compensation to revenue | 0.78 | 0.1 | 0.14 | 0.04 | 0.05 | |
| Graham number | 19.32K | 833.43 | 84.39 | 37.76 | 25.36 | |
| ROIC | -1.77 | -1.12 | -0.57 | -0.17 | -0.38 | |
| Return on tangible assets | -6.12 | -1.05 | -1.73 | -0.18 | -0.51 | |
| Graham Net | -3.92K | 7.22 | -18.68 | -0.19 | -2.93 | |
| Working capital | -581.91K | 6.08M | 10.06M | 46.66M | -4.2M | |
| Tangible asset value | -7.32M | 2.06M | -12M | 18.07M | -13.7M | |
| Net current asset value | -7.97M | 1.83M | -12.2M | 17.14M | -22.87M | |
| Invested capital | 0 | 0 | 0 | 0.03 | 0.21 | |
| Average receivables | 2.85M | 2.88M | 3.46M | 5.18M | 16.68M | |
| Average payables | 7.02M | 6.97M | 7.06M | 11.82M | 15.54M | |
| Average inventory | 5.66M | 5.67M | 5.72M | 10M | 13.17M | |
| Days sales outstanding | 59.82 | 57.72 | 86.8 | 68.37 | 156.7 | |
| Days payables outstanding | 571.8 | 377.3 | 380.78 | 571.42 | 192.91 | |
| Days of inventory on hand | 337.93 | 238.34 | 238.7 | 483.22 | 163.69 | |
| Receivables turnover | 6.1 | 6.32 | 4.21 | 5.34 | 2.33 | |
| Payables turnover | 0.64 | 0.97 | 0.96 | 0.64 | 1.89 | |
| Inventory turnover | 1.08 | 1.53 | 1.53 | 0.76 | 2.23 | |
| ROE | -5.63 | -0.76 | -3.83 | -0.14 | -0.42 | |
| Capex per share | -47.9 | -1.12 | -0.08 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-03-31 for Q3
| Metric | History | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.75 | 1 | 0.86 | 0.88 | 0.82 | |
| Net income per share | -1.41 | -0.81 | -1.09 | -0.44 | -1.79 | |
| Operating cash flow per share | -0.49 | -0.27 | -0.15 | -0.33 | -0.31 | |
| Free cash flow per share | -0.49 | -0.27 | -0.15 | -0.33 | -0.31 | |
| Cash per share | 2.57 | 2.11 | 1.57 | 1.34 | 0.93 | |
| Book value per share | 7.91 | 5.85 | 4.36 | 4 | 2.06 | |
| Tangible book value per share | -1.04 | -0.58 | -4.19 | -0.84 | -0.74 | |
| Share holders equity per share | 7.91 | 5.85 | 4.36 | 4 | 2.06 | |
| Interest debt per share | 1.48 | 1.21 | 0.42 | 0.47 | 0.72 | |
| Market cap | 137.5M | 117.83M | 73.72M | 35.66M | 32.07M | |
| Enterprise value | 117.8M | 96.53M | 44.1M | 12.78M | 25.71M | |
| P/E ratio | -1.35 | -1.55 | -0.66 | -0.77 | -0.15 | |
| Price to sales ratio | 10.2 | 5.02 | 3.37 | 1.54 | 1.33 | |
| POCF ratio | -15.67 | -18.75 | -19.45 | -4.04 | -3.52 | |
| PFCF ratio | -15.67 | -18.75 | -19.45 | -4.04 | -3.52 | |
| P/B Ratio | 0.96 | 0.86 | 0.66 | 0.34 | 0.52 | |
| PTB ratio | 0.96 | 0.86 | 0.66 | 0.34 | 0.52 | |
| EV to sales | 8.74 | 4.11 | 2.01 | 0.55 | 1.06 | |
| Enterprise value over EBITDA | -6.14 | -4.87 | -1.74 | -1.44 | -0.51 | |
| EV to operating cash flow | -13.42 | -15.36 | -11.63 | -1.45 | -2.82 | |
| EV to free cash flow | -13.42 | -15.36 | -11.63 | -1.45 | -2.82 | |
| Earnings yield | -0.19 | -0.16 | -0.38 | -0.32 | -1.66 | |
| Free cash flow yield | -0.06 | -0.05 | -0.05 | -0.25 | -0.28 | |
| Debt to equity | 0.14 | 0.02 | 0.07 | 0.08 | 0.27 | |
| Debt to assets | 0.47 | 0.48 | 0.84 | 0.53 | 0.64 | |
| Net debt to EBITDA | 1.03 | 1.07 | 1.17 | 2.58 | 0.13 | |
| Current ratio | 1.2 | 0.96 | 0.91 | 0.87 | 0.97 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.34 | 0.33 | 0.14 | 0.76 | 0.17 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0.36 | 0.38 | 0.34 | 0.31 | |
| Research and developement to revenue | 0.03 | 0.2 | 0.1 | 0.21 | 0.15 | |
| Intangibles to total assets | 0.6 | 0.57 | 0.94 | 0.57 | 0.49 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0.11 | 0.05 | 0.07 | 0.05 | 0.05 | |
| Graham number | 15.83 | 10.31 | 10.33 | 6.27 | 9.1 | |
| ROIC | -0.14 | -0.15 | -0.68 | -0.09 | -0.62 | |
| Return on tangible assets | -0.23 | -0.17 | -3.11 | -0.12 | -0.62 | |
| Graham Net | -2.9 | -2.09 | -2.01 | -2.18 | -1.77 | |
| Working capital | 16.33M | -4.2M | -8.96M | -13.03M | -2.41M | |
| Tangible asset value | -18.89M | -13.7M | -107.27M | -22.15M | -21.92M | |
| Net current asset value | -28.39M | -22.87M | -27.19M | -30.75M | -29.74M | |
| Invested capital | 0.19 | 0.21 | 0.1 | 0.12 | 0.35 | |
| Average receivables | 25.61M | 25.58M | 22.31M | 22.99M | 25.3M | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 16.57M | 16.45M | 16.44M | 16.56M | 15.22M | |
| Days sales outstanding | 188.44 | 107.99 | 88.89 | 89.47 | 102.7 | |
| Days payables outstanding | 108.72 | 134 | 0 | 0 | 87.01 | |
| Days of inventory on hand | 109.03 | 113.71 | 155.52 | 137.65 | 108.59 | |
| Receivables turnover | 0.48 | 0.83 | 1.01 | 1.01 | 0.88 | |
| Payables turnover | 0.83 | 0.67 | 0 | 0 | 1.03 | |
| Inventory turnover | 0.83 | 0.79 | 0.58 | 0.65 | 0.83 | |
| ROE | -0.18 | -0.14 | -0.25 | -0.11 | -0.87 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Frequently Asked Questions
What is Aytu BioPharma, Inc. stock symbol ?
Aytu BioPharma, Inc. is a US stock , located in Englewood of Colorado and trading under the symbol AYTU
Is Aytu BioPharma, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $11. The lowest prediction is $11 and the highest is $11
What is AYTU stock prediction ?